Kati Vandermeulen

1.8k total citations · 1 hit paper
19 papers, 713 citations indexed

About

Kati Vandermeulen is a scholar working on Infectious Diseases, Virology and Hepatology. According to data from OpenAlex, Kati Vandermeulen has authored 19 papers receiving a total of 713 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Infectious Diseases, 14 papers in Virology and 4 papers in Hepatology. Recurrent topics in Kati Vandermeulen's work include HIV/AIDS drug development and treatment (19 papers), HIV Research and Treatment (14 papers) and HIV/AIDS Research and Interventions (8 papers). Kati Vandermeulen is often cited by papers focused on HIV/AIDS drug development and treatment (19 papers), HIV Research and Treatment (14 papers) and HIV/AIDS Research and Interventions (8 papers). Kati Vandermeulen collaborates with scholars based in Belgium, United States and United Kingdom. Kati Vandermeulen's co-authors include Brian Wynne, Lesley Kahl, Martin Gartland, Michael Aboud, Mark Underwood, Elizabeth A. Blair, Cynthia Brinson, Thomas N. Kakuda, Josep M. Llibre and Pierre‐Marie Girard and has published in prestigious journals such as The Lancet, AIDS and Journal of Antimicrobial Chemotherapy.

In The Last Decade

Kati Vandermeulen

19 papers receiving 677 citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies

2018 243 citations Josep M. Llibre, Chien‐Ching Hung et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kati Vandermeulen Belgium	12	651	480	177	133	54	19	713
Christiane Moecklinghoff Germany	14	592 0.9×	492 1.0×	258 1.5×	103 0.8×	57 1.1×	34	728
Catherine Granier United Kingdom	8	908 1.4×	699 1.5×	267 1.5×	141 1.1×	30 0.6×	10	976
Michael Aboud United Kingdom	13	950 1.5×	703 1.5×	407 2.3×	172 1.3×	43 0.8×	31	1.1k
Martin Gartland United Kingdom	11	794 1.2×	634 1.3×	262 1.5×	117 0.9×	26 0.5×	19	866
Naomi Givens United Kingdom	9	566 0.9×	399 0.8×	200 1.1×	107 0.8×	30 0.6×	17	609
Ya-Pei Liu United States	10	465 0.7×	347 0.7×	167 0.9×	74 0.6×	30 0.6×	16	518
Arturo Ciccullo Italy	13	430 0.7×	307 0.6×	148 0.8×	126 0.9×	15 0.3×	70	510
José Valdez Madruga Brazil	7	775 1.2×	600 1.3×	154 0.9×	181 1.4×	21 0.4×	11	829
Awny Farajallah United States	8	599 0.9×	408 0.8×	243 1.4×	85 0.6×	26 0.5×	12	649
Maura Laverty United States	8	356 0.5×	243 0.5×	59 0.3×	181 1.4×	31 0.6×	15	517

Countries citing papers authored by Kati Vandermeulen

Since Specialization

Citations

This map shows the geographic impact of Kati Vandermeulen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kati Vandermeulen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kati Vandermeulen more than expected).

Fields of papers citing papers by Kati Vandermeulen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kati Vandermeulen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kati Vandermeulen. The network helps show where Kati Vandermeulen may publish in the future.

Co-authorship network of co-authors of Kati Vandermeulen

This figure shows the co-authorship network connecting the top 25 collaborators of Kati Vandermeulen. A scholar is included among the top collaborators of Kati Vandermeulen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kati Vandermeulen. Kati Vandermeulen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Sutton, Kenneth, Jerome De Vente, Roger LeBlanc, et al.. (2022). Long-Term Efficacy, Safety, and Durability of Cabotegravir and Rilpivirine as 2-Drug Oral Maintenance Therapy After 6 Years of Study. Open Forum Infectious Diseases. 9(4). ofac067–ofac067. 2 indexed citations

Llibre, Josep M., Luís F. López‐Cortés, Brian Wynne, et al.. (2022). Brief Report: Evaluation of Inflammation and Atherogenesis Biomarkers Through 148 Weeks Postswitch to Dolutegravir and Rilpivirine in SWORD-1/SWORD-2. JAIDS Journal of Acquired Immune Deficiency Syndromes. 91(1). 73–78. 7 indexed citations

Orkin, Chloe, Enrique Bernal, Darrell H. S. Tan, et al.. (2021). Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study. The Lancet HIV. 8(11). e668–e678. 88 indexed citations

Mills, Anthony, Gary Richmond, Cheryl Newman, et al.. (2021). Long-acting cabotegravir and rilpivirine for HIV-1 suppression: switch to 2-monthly dosing after 5 years of daily oral therapy. AIDS. 36(2). 195–203. 25 indexed citations

Wu, Sterling, Feifan Zhang, David Dorey, et al.. (2020). 1029. Long-Term Patient Adherence and Management of Treatment Interruptions With Long-Acting Injectable Cabotegravir + Rilpivirine for Maintenance Therapy in Phase IIb/III Studies. Open Forum Infectious Diseases. 7(Supplement_1). S544–S544. 2 indexed citations

Mills, Anthony, Gary Richmond, Cheryl Newman, et al.. (2020). 116. Antiviral Activity and Safety of Long-acting Cabotegravir (CAB LA) Plus Long-acting Rilpivirine (RPV LA), Administered Every 2 Months (Q2M), in Hiv-positive Subjects: Results from the POLAR Study. Open Forum Infectious Diseases. 7(Supplement_1). S186–S187. 1 indexed citations

Smith, Graham, Keith Henry, Daniel Podzamczer, et al.. (2020). 638. Safety, Efficacy, and Durability of Long-Acting CAB and RPV as Maintenance Therapy for HIV-1 Infection: LATTE-2 Week 256 Results. Open Forum Infectious Diseases. 7(Supplement_1). S379–S380. 2 indexed citations

Wyk, Jean van, Chloe Orkin, Rafael Rubio, et al.. (2020). Brief Report: Durable Suppression and Low Rate of Virologic Failure 3 Years After Switch to Dolutegravir + Rilpivirine 2-Drug Regimen: 148-Week Results From the SWORD-1 and SWORD-2 Randomized Clinical Trials. JAIDS Journal of Acquired Immune Deficiency Syndromes. 85(3). 325–330. 32 indexed citations

Aboud, Michael, Chloe Orkin, Daniel Podzamczer, et al.. (2019). Efficacy and safety of dolutegravir–rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies. The Lancet HIV. 6(9). e576–e587. 77 indexed citations

10.

Llibre, Josep M., Chien‐Ching Hung, Cynthia Brinson, et al.. (2018). Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies. The Lancet. 391(10123). 839–849. 243 indexed citations breakdown →

11.

Walmsley, Sharon, Gary Richmond, Fritz Bredeek, et al.. (2017). Sword 1 and 2: Subgroup Analysis of 48 Week Results by Age, Race and Gender. Open Forum Infectious Diseases. 4(suppl_1). S427–S427. 1 indexed citations

12.

McComsey, Grace A., Sergio Lupo, Lesley Kahl, et al.. (2017). Switch from tenofovir disoproxil fumarate combination to dolutegravir with rilpivirine improves parameters of bone health. AIDS. 32(4). 477–485. 43 indexed citations

13.

Kakuda, Thomas N., Brian Woodfall, Tine De Marez, et al.. (2013). Pharmacokinetic evaluation of the interaction between etravirine and rifabutin or clarithromycin in HIV-negative, healthy volunteers: results from two Phase 1 studies. Journal of Antimicrobial Chemotherapy. 69(3). 728–734. 11 indexed citations

14.

Kakuda, Thomas N., et al.. (2009). Assessment of the steady‐state pharmacokinetic interaction between etravirine administered as two different formulations and tenofovir disoproxil fumarate in healthy volunteers. HIV Medicine. 10(3). 173–181. 27 indexed citations

15.

Schöller‐Gyüre, Monika, Thomas N. Kakuda, Brian Woodfall, et al.. (2009). Effect of steady-state etravirine on the pharmacokinetics and pharmacodynamics of ethinylestradiol and norethindrone. Contraception. 80(1). 44–52. 29 indexed citations

16.

Schöller‐Gyüre, Monika, Wim van den Brink, Thomas N. Kakuda, et al.. (2008). Pharmacokinetic and Pharmacodynamic Study of the Concomitant Administration of Methadone and TMC125 in HIV‐Negative Volunteers. The Journal of Clinical Pharmacology. 48(3). 322–329. 33 indexed citations

17.

Kakuda, Thomas N., Cassy Workman, Keikawus Arastéh, et al.. (2008). Single- and multiple-dose pharmacokinetics of etravirine administered as two different formulations in HIV-1-infected patients. Antiviral Therapy. 13(5). 655–661. 27 indexed citations

18.

Schöller‐Gyüre, Monika, Marta Boffito, Anton Pozniak, et al.. (2008). Effects of Different Meal Compositions and Fasted State on the Oral Bioavailability of Etravirine. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 28(10). 1215–1222. 35 indexed citations

19.

Foudraine, Norbert A., J J de Jong, Gerrit Jan Weverling, et al.. (1998). An open randomized controlled trial of zidovudine plus lamivudine versus stavudine plus lamivudine. AIDS. 12(12). 1513–1519. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact